Currency In USD
| Previous Close | 0.05 |
| Open | 0.04 |
| Day High | 0.06 |
| Day Low | 0.04 |
| 52-Week High | 0.86 |
| 52-Week Low | 0.02 |
| Volume | 1.68M |
| Average Volume | 110.64M |
| Market Cap | 75.16M |
| PE | -0.07 |
| EPS | -0.66 |
| Moving Average 50 Days | 0.1 |
| Moving Average 200 Days | 0.26 |
| Change | -0 |
Data not available
Adaptimmune Announces Delisting from Nasdaq
Newsfile
Oct 20, 2025 11:40 AM GMT
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determin
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Newsfile
Jul 28, 2025 11:30 AM GMT
Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with GalapagosPurchase price is $55m in cash to be paid upon consummation
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Newsfile
May 07, 2025 4:00 PM GMT
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provid